透過您的圖書館登入
IP:18.218.168.16
  • 學位論文

臺灣現行藥品統計法規之探討研究

A Study on the Current Regulations of Statistics for Pharmaceutical Products in Taiwan

指導教授 : 劉仁沛
若您是本文的作者,可授權文章由華藝線上圖書館中協助推廣。

摘要


就以藥品而言,若未有統計的要求列入法規,當我國政府為把關國民健康,面對什麼樣的藥品能夠經由查驗登記核准上市,必定產生標準莫衷一是的情形,因此,建立一套藥品統計法規標準,一來既可使我國藥品製造業者在申請查驗登記核准上市有一定的標準可以依循,二來亦可對我國國民健康作合理的把關。其次,建立標準的方式須仰賴法規的訂定,在藥品查驗登記審查的過程中,必定會引用到許多科學性的資料,而科學性資料的建立有往往是許多統計資料所組成,因而對統計數據建立一套標準的法規以供依循,乃是一門相當重要的課題。故此,本研究首先以我國藥物行政單位(即衛生署藥政處)在藥品查驗登記過程中統計之運用現況進行觀察,剖析現行組織運作及條文施行問題所在,以釐清問題意識,並藉由問題的提出與實務情形作一比對,整理出現行法規可能未臻完善之處。最後,本論文以比較法的方式,選擇世界具有代表性的藥品先進國家組織,就藥品統計相關法規單位組織架構及法規予以介紹,進一步分析比較我國現行藥品統計相關組織架構及法規,並提出本論文的詮釋與見解,期能提供相關單位參考。

並列摘要


In registration of medicine, if there is no adequate and feasible statistical principles in the regulation requirements, the pharmaceutical industry will be in a maze and the people health will not be safeguarded. For this reason, it is essential to establish a statistical principles for medicine to ensure that the criteria of quality, safety, and efficacy are met for the new treatments for the patients in need. Therefore, this thesis surveyed the structure and regulations about statistical principles in the jurisdiction for the Bureau of Pharmaceutical Affairs, Department of Health, Taiwan for registration of a drug. The comparative law approach was adopted in the methodology. By examining the ICH and the regulatory agencies of Europe, Japan and the USA, we concluded that it is essential in our government to establish an adequate unit, draw up feasible legislations and technical requirements, and recruit biostatistical experts. Finally, we attempted to provide suggestions about the possible improvement of regulations in applications of statistics to registration of pharmaceutical products.

並列關鍵字

statistics medicine product ICH CDER PMDA EMEA

參考文獻


農委會(2002)《糧食管理法施行細則》。行政院農委會,台北市。農委會法規查詢系統http://www.coa.gov.tw/info_lawactive.php?cat=info_lawactive (Access on 18 Sep 2008)
LONGMAN Dictionary of Contemporary English ONLINE。 http://www.ldoceonline.com/ (Access on 17 Sep 2008)
FDA(2001b)《Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals》. Center for Drug Evaluation and Research, the United States Food and Drug Administration, Rockville, MD. CDER home page http://www.fda.gov/cder/ (Access on 2 Dec 2008)
EMEA(2000)《Points to Consider on Switching between Superiority and Non-Inferiority》. European Medicines Agency, London, the United Kingdom. EMEA home page http://www.emea.europa.eu/home.htm (Access on 3 Dec 2008)
ICH(1993)《E7:Studies in Support of Special Populations: Geriatrics》. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH home page http://www.ich.org/ (Access on 22 Dec 2008)

延伸閱讀